Affiliation:
1. 2nd Department of Gastroenterology, Emergency University Hospital, „Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Abstract
Corticosteroids have an important role in induction of remission in inflammatory bowel disease, but they are not an indicated for maintenance treatment as they are associated with many side effects. Despite new effi cient therapeutic options for maintaining remission, there is an excess in prescribing steroids in inflammatory bowel disease. Corticosteroid use was evaluated in international cohorts given that steroid free remission and avoiding serious side-effects of corticosteroids is a desirable goal. We discuss the role and the evidences on a secure web-based steroid assessment tool (SAT) which can be used as an instrument of evaluation of corticosteroid use, a quality indicator in inflammatory bowel disease.
Publisher
CMMB-Colegiul Medicilor Municipiul Bucuresti
Reference53 articles.
1. M. Salice, F. Rizzello, C. Calabrese, L. Calandrini, and P. Gionchetti, “A current overview of corticosteroid use in active ulcerative colitis,” Expert Rev. Gastroenterol. Hepatol., vol. 13, no. 6, pp. 557–561, Jun. 2019.
2. 2. M. V. Lenti et al., “Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign,” Dig. Liver Dis., vol. 52, no. 1, pp. 44–50, 2020.
3. 3. G. G. Kaplan et al., “The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology,” J. Can. Assoc. Gastroenterol., 2019.
4. 4. G. C. Nguyen et al., “Modifi ed Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease,” Inflamm. Bowel Dis., 2017.
5. 5. C. A. Lamb et al., “British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults,” Gut. 2019.